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L’administration de 10-4 M de DHLA dans le liquide de perfusion des 
cœurs isolés n’a pas conduit à une amélioration de la dysfonction 
contractile cardiaque qui caractérise la séquence d’IR. En revanche, 
dans nos expériences réalisées in vitro sur GR, en présence de DHLA, 
l’ef ux potassique extracellulaire, qui signe la dégradation précoce 
des membranes érythrocytaires par le stress oxydant, a été diminué 
de manière signi cative et dose-dépendante. Le DHLA était plus 
ef cace que l’AL aux mêmes concentrations et offrait une protection 
plus importante que celle du Trolox.
En conclusion, il apparaît que, dans nos conditions expérimentales, 
le myocarde ischémique n’est pas sensible au traitement par 
10-4 M de DHLA. En revanche, les membranes érythrocytaires sont 
protégées de manière très signi cative par ce composé antioxydant. 
Nos résultats ouvrent des perspectives quant à un possible béné ce 
de l’utilisation du DHLA ou de l’AL dans certaines pathologies où 
le stress oxydant intéresse principalement le territoire vasculaire 
(diabète).
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PROKINETICIN RECEPTOR SIGNALING IN 
CARDIOVASCULAR FUNCTION: FOES OR FRIENDS ?
C. NEBIGIL-DESAUBRY 1
1 CNRS-Université Strasbourg, Strasbourg-Illkirch, France
Prokineticins are secreted peptides that activate two receptors. 
We investigated the role of each receptor in heart by 
generating transgenic (TG) mice overexpressing PKR1 or PKR2 
in cardiomyocytes. TG-PKR1 displayed an increased number of 
epicardial-derived progenitor cells (EPDCs), capillary density 
and vessels, without inducing any cardiomyocyte abnormalities. 
Coculturing EPDCs with H9c2 cardiomyoblasts overexpressing PKR1 
upragulates prokineticin-2 as a paracrine factor that promotes 
EPDC differentiation into endothelial and smooth muscle cells, 
mimicking our transgenic model. Exogenous prokineticin-2 induces 
neonatal and adult EPDC differentiation. These prokineticin-2 
effects were abolished in EPDCs from mice with PKR1-null mutation, 
indicating involvement of PKR1. This study provides a novel insight 
for possible therapeutic strategies aiming at restoring pluripotency 
of adult EPDCs to promote neovasculogenesis by induction 
of cardiomyocyte PKR1 signaling. TG-PKR2 exhibit increased 
hypertrophic gene expressions and increased left ventricular end-
systolic and diastolic diameters without cardiac dysfunction at the 
age of 24 weeks. TG hearts exhibit abnormal endothelial cell shape 
and ultrastructure, changed cellular distribution of a tight junction 
protein ZO-1, and vascular leakage in heart. The application of 
media conditioned by H9c2 cardioblast cells overexpressing PKR2 
disturbed ZO-1 localization in H5V endothelial cells, mimicking 
the TG model. These  ndings showed that cardiomyocyte PKR2 
signalling leads to eccentric hypertrophy in an autocrine regulation 
and impaired endothelial integrity in a paracrine regulation.
Our  ndings should facilitate the discovery of speci c agonist and 
antagonist targeting PKR1 and PKR2 for possible use of treatment 
of ischemic heart diseases.
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KINASE—DEPENDENT MMP-9 AND OSTEOPONTIN 
EXPRESSION
M.-A. RENAULT 1,2, J. RONCALLI 2, J. TONGERS 2, T. THORNE  2, 
S. MISENER 2, O.-L. VOLPERT 3, S. METHA 4, A. BURG 4, 
C. LUEDEMANN 4, G. QIN 2, R. KISHORE 2, D.-W. LOSORDO
1 Inserm U828, Bordeaux, France
2 Feinberg Cardiovascular Research Institute, Northwestern 
University, Chicago, USA
3 Department of Urology, Northwestern University, Chicago, USA
4 st Elizabeth Medical Center, Boston, USA
Rationale and Objectives — The morphogen Sonic Hedgehog (Shh) is 
known to promote neovascularization in adults via indirect induction 
of pro-angiogenic cytokine expression by  broblasts. Direct effects 
of Shh on endothelial cell (EC) function and angiogenesis, however, 
have not been characterized. Accordingly, we performed a series of 
in vitro and in vivo studies to evaluate the direct effects of Shh on 
EC and to investigate certain mechanisms by which Shh modulates 
angiogenesis.
Methods and Results — Our data disclose that Shh promotes 
capillary morphogenesis (tube length on Matrigel™ increased to 
271±50 % of the length in untreated cells), induces EC migration 
(191±35 %) and increases EC expression of matrix metalloproteinase 
9 (MMP-9) and osteopontin (OPN), which are shown to be essential 
for Shh-induced angiogenesis both in vitro and in vivo. Shh effects 
in ECs, however, occur while Gli-dependent transcription is not 
modulated. Furthemore, our studies show that changes in gene 
expression and EC migration are mediated by Shh induction of 
Rho. The Rho dependence of Shh-induced EC angiogenic activity is 
documented in vitro using dominant negative constructs for RhoA 
and Rho kinase (ROCK), showing that RhoA and ROCK blockade 
attenuates Shh induced migration and tube formation, as well as 
the Shh induced expression of MMP-9 and OPN. In vivo in the mouse 
corneal angiogenesis model pharmacologic inhibition of ROCK 
blocks Shh induced angiogenesis, con rming the ROCK dependence 
of this process. Furthermore, in MMP-9 and OPN null mice Shh 
induced angiogenesis also blocked, indicating that Shh induced 
angiogenesis is also dependent on MMP-9 and OPN expression
Conclusion — These data elucidate an entirely novel, “non-
classical” pathway by which Shh directly modulates EC phenotype 
and angiogenic activity.
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Background — Vascular Endothelial Growth Factor (VEGF) and 
Hypoxia Inducible Factor-1α (HIF-1α) are both positive regulators 
of angiogenesis. The soluble form of VEGF receptor 1 (sVEGFR1 or 
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sFlt-1) traps circulating VEGF and is therefore anti-angiogenic. An 
emerging concept is that adenosine, known for its cardioprotective 
effects, is a major factor driving angiogenesis, thus contributing 
to the repair of the ischemic heart. The aims of the present study 
were (1) to characterize the effects of adenosine on VEGF and sFlt-
1, (2) to determine which subtype(s) of adenosine receptor (A1, 
A2a, A2b, A3) promote these effects.
Methods — Human primary cardiac  broblasts, myo broblasts, and 
blood monocyte-derived macrophages were treated with adenosine 
(10 m) or adenosine analogs, and/or LPS (100 ng/ml). In vitro 
formation of microtubules by human coronary artery cells (HCAEC) 
was used as an angiogenesis assay. Transgenic mice with cardiac-
speci c and inducible overexpression of A1 and A2a receptors were 
used. Wild type (WT) and A3 adenosine receptor knocked-out mice 
were subjected to transverse aortic constriction (TAC). ELISA, real-
time quantitative PCR,  ow cytometry and immunoblotting were 
used to measure levels of VEGF, HIF-1α and sFlt-1.
Results — Adenosine increased VEGF mRNA and protein expression 
by human primary  broblasts, myo broblasts and macrophages 
(22-fold increase in adenosine- and LPS-treated macrophages, 
P<0.0001). Up-regulation of VEGF by adenosine was replicated using 
agonists of A2a (C141) and A3 (IB-MECA) receptors, and inhibited by 
antagonists of A2a (SCH58261) and A2b (MRS1754) receptors. sFlt-1 
production induced by LPS was decreased by 43 % in the presence 
of adenosine (P=0.006). Adenosine enhanced the formation of a 
network of microtubules by HCAEC and this effect was dampened 
in the presence of VEGF-blocking antibody. Over-expression of 
the A2a receptor in mice enhanced VEGF and HIF-1α expression. 
TAC increased VEGF and HIF-1α expression in the heart, an effect 
inhibited in A3-de cient mice.
Conclusion — Adenosine plays a major role in angiogenesis through 
up-regulation of the pro-angiogenic VEGF and down-regulation 
of the anti-angiogenic sFlt-1. These effects appear to be mainly 
mediated by the A2a receptor. Our results suggest that both A2a 
and A3 receptors play signi cant roles in adenosine-mediated 
angiogenesis.
D004
PHARMACOLOGICAL BLOCKADE OF ANGIOTENSIN II 
TYPE 2 RECEPTOR INHIBITS TUMOR GROWTH 
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Angiotensin II type 2 receptor (AT2R) stimulation is thought to 
induce vasodilation and apoptosis. Nevertheless, its role remains 
controversial. In hypertension and aging, AT2R might promote 
vasoconstriction and cell growth. In cancer cells, AT2R is highly 
expressed but its role remains poorly understood. Thus, we 
investigated the role of AT2R in tumor growth, hypothesizing that 
AT2R affects cell proliferation and/or tumor vascularization.
Tumor induction by 3-methylcholanthrene was signi cantly delayed 
in AT2R knockout mice, suggesting a role for AT2R in tumor initiation. 
Tumor growth after subcutaneous injection of LL/2 cancer cells in 
C57/BL6 mice treated with PD123,319, an AT2R antagonist, was 
decreased when PD123,319 was given at an early stage, suggesting 
that AT2R is also involved in tumor promotion. In vitro proliferation 
of LL/2 cells was reduced by PD123,319 with a signi cant decrease 
in Ki67 expression and ERK1/2 phosphorylation. In addition, tumor 
vascular density, measured by CD31 labeling and angiogenesis using 
the aortic ring assay on Matrigel®, were reduced by PD123,319 and 
in AT2R-null mice. Therefore, we uncovered a novel mechanism by 
which AT2R promotes tumor development favoring both malignant 
cancer cell proliferation and tumor angiogenesis. Thus, blocking 
AT2R could be a new approach in tumor therapy.
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Increased permeability of, and bleeding from, microvessels within 
the atheromatous arterial wall participate in atherothrombosis 
progression. The VEGF family and angiopoietin system components 
govern microvessel development and maturation. Serine protease 
activities are proportional to atherothrombosis progression and 
linked to intraplaque hemorrhage. Here we investigated the 
relationship between angiogenic factors and proteases in human 
hemorrhagic and non-hemorrhagic atheromatous carotid samples 
by immunohistochemistry, in situ hybridization and ELISA. 
Plaque activity of plasmin and leukocyte elastase and proteolysis 
of angiogenic factors by plaque extracts were determined. 
Smooth muscle cell migration induced by hemorrhagic and non-
hemorrhagic plaques was assessed. The absence of á-actin-positive 
cells characterized microvessels in hemorrhagic areas in spite of 
similar expression of VEGF and angiopoietin system components in 
microvessels of hemorrhagic and non-hemorrhagic areas. However, 
VEGF, PlGF and angiopoietin-1 levels were signi cantly decreased 
in hemorrhagic compared to non-hemorrhagic plaques, whereas 
angiopoietin-2 did not change and soluble Tie-2 levels increased. 
Consequently, smooth muscle cell migration stimulatory activity of 
hemorrhagic plaques was reduced. Recombinant PlGF, VEGF and 
angiopoietin-1 added to plaque extracts were only degraded by 
hemorrhagic lesions. This proteolysis was prevented by inhibitors of 
plasmin and elastase, whose activity was increased in hemorrhagic 
plaques. No degradation was observed for angiopoietin-2. Decreased 
angiogenic factor levels caused by proteolysis may destabilize 
plaque microvessels via impairment of mural cell recruitment, thus 
leading to a vicious circle of intraplaque hemorrhages and lesion 
progression.
